Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer

Journal of Clinical Oncology

Volumn 30, Issue 6, 2012, Pages 587-592

  Amir, Eitan ^a   Miller, Naomi ^a   Geddie, William ^a   Freedman, Orit ^a   Kassam, Farrah ^a   Simmons, Christine ^a   Oldfield, Maria ^a   Dranitsaris, George ^a   Tomlinson, George ^a   Laupacis, Andreas ^a,b   Tannock, Ian F ^a   Clemons, Mark ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c OTTAWA REGIONAL CANCER CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TRASTUZUMAB;

ADULT; AGED; ANXIETY; ARTICLE; ASPIRATION BIOPSY; BASAL CELL CARCINOMA; BREAST BIOPSY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; COHORT ANALYSIS; DISEASE SEVERITY; FEMALE; FOLLOW UP; GENERAL CONDITION DETERIORATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; METASTASIS; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAIN; PATIENT SATISFACTION; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT FAILURE; TREATMENT PLANNING; TUMOR BIOPSY;

ANTIBODIES, MONOCLONAL, HUMANIZED; BREAST NEOPLASMS; FEMALE; HUMANS; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL;

EID: 84857568955     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.33.5232     Document Type: Article

References (28)

1. Brennan MJ, Donegan WL, Appleby DE: The variability of estrogen receptors in metastatic breast cancer. Am J Surg 137:260-262, 1979 (Pubitemid 9092126)
2. Holdaway IM, Bowditch JV: Variation in receptor status between primary and metastatic breast cancer. Cancer 52:479-485, 1983 (Pubitemid 13073476)
3. Pusztai L, Viale G, Kelly CM, et al: Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis. Oncologist 15:1164-1168, 2010
4. National Comprehensive Cancer Network: Practice Guidelines in Oncology: Breast Cancer v. 1.2010. http://www.nccn.org/professionals/physician-gls/f- guidelines.asp#site
5. Li BD, Byskosh A, Molteni A, et al: Estrogen and progesterone receptor concordance between primary and recurrent breast cancer. J Surg Oncol 57:71-77, 1994 (Pubitemid 24299653)
6. Regitnig P, Schippinger W, Lindbauer M, et al: Change of HER-2/neu status in a subset of distant metastases from breast carcinomas. J Pathol 203: 918-926, 2004 (Pubitemid 39089280)
7. Simmons C, Miller N, Geddie W, et al: Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? Ann Oncol 20:1499-1504, 2009
8. Thompson AM, Jordan LB, Quinlan P, et al: Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: The Breast Recurrence in Tissues Study (BRITS). Breast Cancer Res 12:R92, 2010
9. Liedtke C, Broglio K, Moulder S, et al: Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol 20:1953-1958, 2009
10. Karlsson E, Lindstrom LS, Wilking U, et al: Discordance in hormone receptor status in breast cancer during tumor progression. J Clin Oncol 28: 116s, 2010 (suppl; abstr 1009)
11. Wilking U, Karlsson E, Skoog L, et al: HER2 status in a population-derived breast cancer cohort: Discordances during tumor progression. Breast Cancer Res Treat 125:553-561, 2011
12. Bussolati G, Leonardo E: Technical pitfalls potentially affecting diagnoses in immunohistochemistry. J Clin Pathol 61:1184-1192, 2008
13. Diaz LK, Sneige N: Estrogen receptor analysis for breast cancer: Current issues and keys to increasing testing accuracy. Adv Anat Pathol 12:10-19, 2005 (Pubitemid 40614485)
14. Hammond ME, Hayes DF, Dowsett M, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28:2784-2795, 2010
15. Gail M, Simon R: Testing for qualitative interactions between treatment effects and patient subsets. Biometrics 41:361-372, 1985
16. Perez EA, Suman VJ, Davidson NE, et al: HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol 24:3032-3038, 2006 (Pubitemid 46638937)
17. Badve SS, Baehner FL, Gray RP, et al: Estrogen- and progesterone-receptor status in ECOG 2197: Comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. J Clin Oncol 26:2473-2481, 2008
18. Lindstrom L, Howell S, Astrom G, et al: Controversies in the management of metastatic breast cancer: Biologic evaluation of breast cancer - Should metastases be biopsied? Am Soc Clin Oncol Ed Book e7-e12, 2010
19. Khasraw M, Brogi E, Seidman AD: The need to examine metastatic tissue at the time of progression of breast cancer: Is re-biopsy a necessity or a luxury? Curr Oncol Rep 13:17-25, 2011
20. Curigliano G, Bagnardi V, Viale G, et al: Should liver metastases of breast cancer be biopsied to improve treatment choice? Ann Oncol [epub ahead of print on February 22, 2011]
21. Hoefnagel LD, van de Vijver MJ, van Slooten HJ, et al: Receptor conversion in distant breast cancer metastases. Breast Cancer Res 12:R75, 2010
22. Hodi Z, Chakrabarti J, Lee AH, et al: The reliability of assessment of oestrogen receptor expression on needle core biopsy specimens of invasive carcinomas of the breast. J Clin Pathol 60:299-302, 2007 (Pubitemid 46447747)
23. Mann GB, Fahey VD, Feleppa F, et al: Reliance on hormone receptor assays of surgical specimens may compromise outcome in patients with breast cancer. J Clin Oncol 23:5148-5154, 2005
24. Amir E, Clemons M: Should a biopsy be recommended for confirmation of metastatic disease in women with breast cancer? Lancet Oncol 10:933-935, 2009
25. Kocjan G, Chandra A, Cross P, et al: BSCC Code of Practice: Fine needle aspiration cytology. Cytopathology 20:283-296, 2009
26. Wu JM, Fackler MJ, Halushka MK, et al: Heterogeneity of breast cancer metastases: Comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clin Cancer Res 14:1938-1946, 2008 (Pubitemid 351551102)
27. Coleman RE: Skeletal complications of malignancy. Cancer 80:1588-1594, 1997
28. Amir E, Ooi WS, Simmons C, et al: Discordance between receptor status in primary and metastatic breast cancer: An exploratory study of bone and bone marrow biopsies. Clin Oncol (R Coll Radiol) 20:763-768, 2008